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Background: The expression of the receptor for advanced glycation end products (RAGE)
has an impact on the mechanisms giving rise to characteristic features of various cancer cells.
The purpose of this study was to elucidate the clinicopathological relevance of the level of
RAGE expression in patients with hepatocellular carcinoma (HCC) and to explore the effect
of RAGE expression on the characteristic features of HCC.
Methods: The expression of RAGE was assessed in paired cancer and noncancerous tissues
with HCC, using reverse-transcription polymerase chain reaction (RT-PCR), and immuno-
histochemistry. The quantitative RT-PCR data were analyzed in association with the clini-
copathological factors of the patients with HCC. In in vitro experiments, the survival of
RAGE-transfected Cos7 and mock-transfected Cos7 cells was compared under hypoxic
conditions. In addition, after reducing RAGE levels in RAGE-transfected Cos7 cells by
siRNA, similar experiments were performed.
Results: The expression of RAGE mRNA was lower in normal liver than in hepatitis and
highest in HCC. Furthermore, in HCC, it was high in well- and moderately differentiated
tumors but declined as tumors dedifferentiated to poorly differentiated HCC. Furthermore,
HCC lines resistant to hypoxia were found to have higher levels of RAGE expression, and
RAGE transfectant also showed signiﬁcantly prolonged survival under hypoxia.
Conclusions: Our results suggest that HCC during the early stage of tumorigenesis with less
blood supply may acquire resistance to stringent hypoxic milieu by hypoxia-induced RAGE
expression.
Key Words: Hepatocellular carcinoma ( HCC )—Receptor for advanced glycation end-products
( RAGE )—Hypoxia-Reverse-transcription polymerase chain reaction ( RT-PCR )—Immunohis-
tochemistry.
Although many cancers arise from chronic
inﬂammation, the relationships between carcinogen-
esis, cancer promotion, and its molecular character-
istics remain poorly understood. Hepatocellular
carcinoma (HCC), which typiﬁes an inﬂammation-
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923related tumor, is one of the most common malig-
nancies in the world, especially in Asia and Africa.
Japan has a high incidence of chronic viral hepatitis,
cirrhosis, and HCC. The resolution of inﬂammatory
activity at the molecular level may correlate with
prevention of hepatocarcinogenesis and cancer pro-
motion.
The receptor for advanced glycation end-products
(RAGE) is a multiligand receptor classiﬁed as an
immunoglobulin superfamily cell surface molecule
and acts as a counter-receptor for high-mobility
group box 1 (HMGB1),
1 advanced glycation end-
products (AGEs), S100/calgranulins, and amyloid-b
peptides. These interactions trigger the activation of
key cell signaling pathways (e.g., p38 and p44/42
MAP kinase,
2 NF-jB, cdc42/rac,
3 and the generation
of reactive oxygen species, and result in the produc-
tion of proinﬂammatory cytokines.
5 RAGE-mediated
proinﬂammatory processes are now considered to
contribute to the progression of many chronic dis-
eases, such as neuropathy, nephropathy,
6 macrovas-
cular disease, amyloidoses, inﬂammatory conditions
(e.g., rheumatoid arthritis and inﬂammatory bowel
disease) and sepsis.
5,7 In addition to RAGE-mediated
proinﬂammatory events, recent studies have revealed
that the interaction of RAGE and its ligands and the
resultant signaling play a causative role in the char-
acteristic modulation of cancer cell functions, i.e.,
increasing tumor invasion and metastasis.
8 Further-
more, several clinical studies have demonstrated the
(strong) association of RAGE expression with the
malignant potential of various cancers such as gastric
cancer,
9 colon cancer,
10,11 common bile duct can-
cer,
12 pancreatic cancer,
13 and prostate cancer,
14 al-
though one report showed a reverse correlation
between RAGE expression and tumor progression.
15
Thus, RAGE expression may be expected play have a
signiﬁcant role in the development of HCC, although
no data have been reported for this tumor. In terms
of HCC, it is known that the pathophysiological
conditions or circumstances surrounding tumorigen-
esis are quite different from those reported for other
cancers. For example, small HCC tumors at an early
stage are continuously exposed to low oxygen and
high glucose as well as the noncancerous hepatic
tissues with cirrhosis in which tissue derangement
occurs.
15 In addition, RAGE is the receptor for
AGEs produced from excessive glucose metabo-
lism,
16 extracellular HMGB1 released from necrotic
cells which could be induced by hypoxia and
inﬂammation, and serum amyloid A (SAA) produced
in response to the proinﬂammatory cytokine IL-6,
17
and these RAGE ligands are possibly generated and/
or released from inﬂamed hepatic tissues. Our central
hypothesis is thus that RAGE expression may play a
particular role in tumorigenesis of HCC, in addition
to the role in the invasive and/or metastatic potential
of cancer cells. With this background, the objectives
of this study were: (1) to clarify the relationship be-
tween RAGE expression and the clinico-pathological
features of HCC and (2) to investigate the functional
role of RAGE expression in HCC development.
MATERIAL AND METHODS
Human samples
From March 2000 to September 2005, 65 patients
with primary HCC were treated surgically in the
Department of Surgical Oncology and Digestive
Surgery, Kagoshima University School of Medicine.
Of these 65 patients, 12 who had diabetes mellitus
and 6 who underwent preoperative therapy were ex-
cluded from the study. RAGE expression for Dia-
betes patients upregulates at various tissues.
18,19,20 A
further 11 patients were excluded because their RNA
samples were degraded. Samples from the remaining
36 patients (30 men and 6 women with a mean age of
67.1 years) were included in the study. Seven patients
(19.4%) were positive for hepatitis B surface antigen
and 21 (58.3%) were positive for the antibody to
hepatitis C virus. Eight patients (22.2%) were nega-
tive for both of these viruses. Twenty-four patients
had chronic hepatitis and four had liver cirrhosis. The
mean tumor size was 49.7 mm (range, 16–150 mm).
The histological grade of each tumor was determined
according to the general rules for the clinical and
pathological study of primary liver cancer (The Liver
Cancer Study Group of Japan, 2000).
21 Four tumors
(11.1%) were well-differentiated HCC, 28 (77.8%)
moderately differentiated HCC, and 4 (11.1%) poorly
differentiated HCC. Postoperative tumor recurrence
was observed for 11 patients (30.6%) (Table 1). For
immunohistochemical study, a further 12 HCC
samples (six well- and six poorly differentiated HCC),
obtained surgically during the same period at JA
Kagoshima Kouseiren Hospital, were added and
used to verify the correlation of RAGE expression
with tumor differentiation. Finally, a total of 48 HCC
nodules (10 well-differentiated HCC, 28 moderately
differentiated HCC, and 10 poorly differentiated
HCC) were studied. As a control study, six normal
liver samples were collected from patients with benign
or metastatic liver tumors. Written informed consent,
recognized by the ethical committees of Kagoshima
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Kouseiren Hospital, was obtained from each patient
before tissue acquisition.
Immunohistochemistry
Consecutive 4-lm sections were cut from each par-
aﬃn-embedding block. Sections were immunostained
by anti-RAGE antibody (Santa-Cruz, CA, USA)
according to the conventional immunoperoxidase
technique. Brieﬂy, after peroxidase blocking with 3%
H2O2/methanol for 10 min, specimens were blocked
with phosphate buffered saline (PBS) containing 5%
normal horse serum (Vector Laboratories, Inc., Bur-
lingame,CA,USA).Anti-RAGEantibodywasusedat
1/200. After overnight incubation at 4 C with the
primary antibody, specimens were brieﬂy washed in
PBS and incubated at room temperature with the
secondary antibody conjugated with peroxidase. The
specimens were then washed in PBS and color-devel-
oped by diaminobenzidine solution (DAKO). After
washing with water, specimens were counterstained
with Meyers hematoxylin (Sigma Chemical Co., St
Louis, MO, USA). Immunostaining of all cases was
performedatonetimetoensurethesameconditionsof
antibody reaction and DAB exposure. A total of
48 HCC nodules (10 well-differentiated HCC, 28
moderately differentiated HCC, and 10 poorly differ-
entiated HCC) were studied. To evaluate the immu-
nohistochemical staining, ten ﬁelds were selected and
expression in 1000 tumor cells (100 cell/ﬁelds) was
evaluated with high-power (·200) microscopy. The
immunohistochemical expression of RAGE was
deﬁned as positive if distinct staining of the cell mem-
brane was observed in at least 10% of tumor cells.
Cell and cell culture
Hepatoma cell lines HepG2, HuH7, HT17, and Li7
were kindly provided by the Cell Resource Center for
Biomedical Research Institute of Development,
Aging, and Cancer, Tohoku University and Hep3B
was obtained from the European Collection of Cell
Cultures. HepG2, Hep3B, and HT17 were cultured
with Dulbeccos Modiﬁed Eagles Medium (DMEM)
(1000 mg/l) and HuH7 and Li7 were cultured with
RPMI. RAGE-transfected Cos7 and its mock-trans-
fectant were kindly provided by Drs. Yamamoto,
Department of Biochemistry and Molecular Vascular
Biology, Kanazawa University. These transfectants
were maintained with DMEM supplemented with
10% Fetal Calf Serum (FCS) in the presence of
650 lg/ml G418. A hypoxic environment was created
by placing a cell culture dish with one pouch of
Anaero Pack into an airtight jar. (Mitsubishi Gas
Chemical Co., Inc., Tokyo, Japan). This created
nearly 0% O2 conditions.
Gene silencing of RAGE with speciﬁc siRNA
Cells were seeded in 12-well plates at a density of
1 · 10
5 cells per well and allowed to adhere over-
night. Then siRNAs for the target gene or its control
oligoribonucleotide mixed with Dharma FECT2
TM
transfection reagent (Dharmacon Inc. Chicago,
USA) was added to the cells and incubated for 48h at
37 C The efﬁcacy of gene silencing was evaluated
using immunoblot analysis.
MTT assay
Cell viability was monitored after incubation for
24, 36, and 48 hours by MTT assay. Brieﬂy, 0.5 mg/
mL 3-[4,5]-2,5-diphenyltetrazolium bromide (MTT)
in fresh medium was added to each well and the cells
were incubated for an additional 3 hours. After-
wards, the blue formazan crystals were dissolved in
1 mL isopropanol and measured spectrophotometri-
cally at 570 nm.
Immunoblot analysis
Whole cell lysates were prepared as per the Santa
Cruz protocol. One milliliter of Radio-Immunopre-
cipitation Assay (RIPA) buﬀer was added to a 100
mm cell culture plate. The plates were gently rocked
for 15 min at 4 C. Adherent cells were scrpaed with a
cell scraper, followed by incubation for 30–60 min on
ice. The cell lysate was microcentrifuged at 10,000g
TABLE 1. Background of patients
Gender
Male 30 (83%)
Female 6 (17%)
Mean age 67.2 years
Virus type
B 7 (19.4%)
C 21 (58.3%)
None 8 (22.2%)
Background of livers
Chronic hepatitis 24 (60.7%)
Liver cirrhosis 4 (11.1%)
Normal liver 8 (22.2%)
Mean tumor size 49.7mm
Histological grade
Well differentiated 4 (11.1%)
Moderately differentiated 28 (77.8%)
Poorly differentiated 4 (11.1%)
Postoperative tumor recurrence 11 (30.6%).
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cell lysate. The supernatant was transferred to a new
microfuge tube and the pellet was discarded. Twelve
microgram lysates were subjected to immunoblot
analysis using a 12.5% sodium dodecyl sulfate (SDS)
-polyacrylamide gel followed by electrotransfer onto
nitrocellulose filters. The filters were immunoreacted
with anti-RAGE antibody (a gift from TORAY Re-
search Institute, Sagamihara, Japan) or with anti-
HMGB1 antibody (BD Biosciences, Tokyo, Japan)
and then incubated with peroxidase-conjugated anti-
goat IgG (Medical and Biological Laboratories, Na-
goya, Japan). The immune complex was visualized
using the Enhanced Chemiluminescence (ECL)
Western blot detection system (PIERCE, Rockford,
IL, USA). The amount of B-actin as an internal
control was also examined using a specific antibody
(Cytoskelton Inc., Denver, CO, USA and Santa
Cruz, CA, USA). At least three independent experi-
ments were performed.
Quantitative RT-PCR
For reverse-transcription PCR (RT-PCR) and real-
time quantitative PCR, total RNA was extracted
from 30 mg frozen tissue using Total RNA Mini
(VIOGENE, CA, USA). For cDNA synthesis, the
RNA samples (1 lg) were converted into cDNA by
reverse transcription (RT) using random primers
(TAKARA, Siga, Japan) according to the manufac-
turers instructions. To estimate the mRNA expres-
sion levels of several genes quantitatively, polymerase
chain reaction (PCR) ampliﬁcation was performed
using a Light-Cycler system (Roche, Mannheim,
Germany) and the Light-Cycler Fast Start DNA
Master SYBER green I kit (Roche). Primers were as
follows: RAGE: 5¢-AAA CAT CAC AGC CCG
GAT TG-3¢ and 5¢-TCC GGC CTG TGT TCA GTT
TC-3¢, HMGB1: 5¢-GCT CAG AGA GGT GGA
AGA CCA-3¢ and 5¢-GGT GCA TTG GGA TCC
TTG AA-3¢ (14) , GAPDH: 5¢-TTG GTA TCG TGG
AAG GAC TCA-3¢ and 5¢-TGT CAT CAT ATT
TGG CAG GTT T-3¢. Ampliﬁcation was carried out
in 20 lL reactions containing 4 mM MgCl2,2lLo f
primer, 2 lL of Light-Cycler-FastStart DNA Master
SYBR green I reagent, and 2 lL of cDNA. Reaction
conditions were an initial incubation at 95 C for 10
min, followed by 50 cycles at 95 C for 10 s for
denaturation, 64 C for 10 s for annealing of the
RAGE primers, 54 C for 10 s for annealing of the
HMGB1 primers and 60 C for 10 s for annealing of
the GAPDH primers and 72 C for 10 s for extension.
Melting curves were obtained according to the
protocol under the following conditions: 0 s dena-
turation period at 95 C, starting temperature of
65 C, end temperatures of 95 C, and rate of tem-
peratures increase of 0.1 C/s. The quantitative value
of the target gene (RAGE mRNA) in each sample
was normalized using GAPDH expression as an
internal control. The quantitative RT-PCR assay was
carried out twice and the mean value was calculated.
Finally, the mRNA expression ratio of cancerous (C)
to noncancerous (N) tissues was calculated using the
following formula: R=log{target gene (C)/GAPDH
(C)}, R=log{target gene (N)/GAPDH (N)}. These
experiments were carried out twice to conﬁrm
reproducibility.
Statistical analysis
Statistical analysis was performed using the JMP
IN version 5.1.2 software system (SAS institute Inc.,
Cary, NC, USA). Each value of mRNA expression
was log transformed before statistical analysis. Gene
expression was compared among normal liver, hep-
atitis, and HCC using Students t-test. The relation-
ships between RAGE-, HMGB1-mRNA expression
levels and clinicopathological features were evaluated
using Students t-test and the Mann–Whitney U test,
as appropriate. Immunohistochemical study of
RAGE in HCC tissues was evaluated using the v
2
test. A p value of less than 0.05 was considered to be
statistically signiﬁcant.
RESULTS
RAGE and HMGB1 expression in normal liver,
hepatitis, and HCC
RAGE antibody yielded a strong band compared
to control mouse lung extracts. Using Western blot-
ting and RT-PCR, protein and mRNA expression of
RAGE and HMGB1 were examined in both cancer
and noncancerous tissues from three cases (Fig. 1a,
b). All 3 cases showed co-expression of RAGE and
HMGB1 protein and mRNA in these tissues.
Quantitative RAGE mRNA expression in HCC and
noncancerous lesions
Comparing the quantitative expression of RAGE
mRNA in paired cancer and noncancerous tissues
(i.e., chronic hepatitis or liver cirrhosis) of 36 cases,
HCC tissues showed signiﬁcantly higher expression
than noncancerous tissues (p < 0.01, Fig. 2a).
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expression in cancer and noncancerous tissues were
higher (p < 0.01 and p = 0.08) than that in normal
liver tissues (i.e., non-inﬂamed liver from benign or
metastatic liver tumor patients) (Fig. 2b).
Relationship between RAGE mRNA expression and
clinicopathological features
To elucidate the biological signiﬁcance of RAGE
expression in HCC, we compared the levels of RAGE
mRNA expression with the clinico-pathological fea-
tures of 36 patients. As shown in Table 2, we noted
signiﬁcant differences in RAGE mRNA expression in
association with gender, age, the levels of protein
induced by vitamin K absence or antagonist (PIV-
KA-II), and postoperative recurrence. In terms of
gender and age, the results are in accordance with a
previous report.
23 The expression levels of RAGE
mRNA tended to be lower in poorly differentiated
tumors compared to well- or moderately differenti-
ated tumors (p = 0.06). Moreover, the levels of
RAGE mRNA showed a negative correlation with
PIVKA-II levels and the presence or absence of
recurrence. There were no signiﬁcant differences
regarding tumor size, intrahepatic metastasis, and
vascular invasion. On the other hand, it should be
noted that a signiﬁcant difference in the levels of
RAGE expression was observed between hepatitis
virus-positive and virus--egative tissues (p < 0.01) in
the study of noncancerous inﬂammatory liver tissues
(i.e., chronic hepatitis or liver cirrhosis) (data not
shown).
RAGE expression and tumor differentiation in HCC
To verify the correlation of RAGE expression with
HCC diﬀerentiation, we carried out an immunohis-
tochemical examination. (Fig. 3a–c) Well- and mod-
erately differentiated HCC showed a high percentage
of RAGE positivity (70% and 64%, respectively);
only 2 of 10 (20%) were positive in poorly differen-
tiated HCC (Fig. 3d). Statistically, there were signif-
icant differences in the rates of positivity between
well- and moderately differentiated HCC and poorly
differentiated HCC.
Control normal
normal
CH HCC
CH HCC
CH HCC
B-actin
GAPDH
Positive
Control
Case 1 Case 2 Case 3
Case 1 Case 2 Case 3
(50kd)
(101bp)
A
B
(148bp)
(29kd)
A
B
e v i t i s o P
l o r t n o c C C H H C normal C C H H C
Control normal CH HCC CH HCC
Case 1 Case 2 Case 3
Case 1 Case 2 Case 3
a
b
FIG. 1. (a) RAGE expression by Western blotting (A) and
RT-PCR (B). (b) HMGB1 expression by Western blotting (A)
and RT-PCR (B). Abbreviations: normal, normal liver; CH,
chronic hepatitis.
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RAGE antibody yielded a strong band on Western
blot analysis of the control RAGE transfected Cos7
cells (Fig. 4a, lane 1). In this experimental setting, the
well-differentiated HCC cell line HuH7 (lane 6) ex-
pressed RAGE protein at a modest level. The poorly
differentiated HCC cell line HT17 (lane 7) expressed
RAGE protein at a low level. Hepatoma cell lines
Hep3B and Li7 (lane 4 and 5), derived from tumors
of unknown state of differentiation, expressed RAGE
protein at a modest level. HepG2 (lane 3) did not
express RAGE protein at all. These results were very
similar to RAGE mRNA expression and depend on
the pathological differentiation of HCC.
Enhanced RAGE expression under hypoxic conditions
Early carcinogenesis occurs in an avascular envi-
ronment and under conditions of hypoxia.
15,23,24 In
order to clarify the role of RAGE expression under
hypoxic conditions, all hepatoma cell lines were cul-
tured in an anaerobic environment. Li7 could survive
for 48 h, Hep3B for 12 h, and HuH7 for 24 h under
such conditions, up to the appearance of signs of cell
death. HepG2 and HT17 rapidly died under anaer-
obic conditions. The RAGE-positive cell lines (Li7,
Hep3B and HuH7) were more tolerant of anaerobic
conditions than RAGE-negative or weakly express-
ing cell lines (HepG2 and HT17). Moreover, RAGE
expression in the cell lines that survived was clearly
upregulated in response to the hypoxic conditions
(Fig. 4b).
Enhancement of cell survival in anaerobic conditions
following RAGE transfection
These ﬁndings led to the hypothesis that RAGE
expression could confer tolerance to hypoxia in HCC.
Therefore, we investigated the survival of RAGE-
transfected and mock-transfected cells under hypoxic
conditions. In continuous incubation under hypoxic
conditions, as expected, RAGE-transfected Cos7 cells
clearly survived longer than mock-transfected Cos7
cells (observed at 36 h and 48 h) (Fig. 5).
Decline of cell survival in hypoxic conditions following
RAGE reduced by siRNA
Consistent with the previous result, reduction of
RAGE expression with anti-RAGE siRNA re-in-
creased susceptibility to hypoxia-induced injury in
RAGE-overexpressed Cos7 transfectant (Fig. 6a,b),
suggesting that RAGE expression might play an
important role in the acquirement of hypoxia-resis-
tant cellular phenotype.
DISCUSSION
Hepatocellular carcinogenesis and associated
tumorigenesis occur in a stringent and restrictive
environment, such as the cirrhotic liver in which tis-
sue oxygen supply is insuﬃcient. Moreover, in the
liver, with a dual blood supply from the hepatic ar-
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FIG. 2. (a) Quantitative RAGE mRNA expression in paired can-
cerous (HCC) and noncancerous tissues from 36 cases. (b) Quan-
titative RAGE mRNA expression in normal liver (n = 6) and
noncancerous and cancerous tissues (n = 36).
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supply are available dependent upon the degree of
liver disorder. The multiligand receptor RAGE is
particularly relevant in this context. The ligands for
RAGE may be produced abundantly during HCC
development. For example, HMGB1 released from
necrotic cells and AGE generated in the process of
higher hepatic glucose metabolism are considered to
be major candidates (i.e., the presence of HMGB1
and carboxymethyl lysine in HCC; data not shown).
Hepatic SAA production in response to IL-6 may
also be included.
19 In addition, RAGE expression
and its downstream signaling are now considered to
play a signiﬁcant role in the progression of various
cancers as well as the development of inﬂammatory
lesions.
Another aspect of the biology of RAGE was
suggested by the features of retinoic acid-induced
neuroblastoma diﬀerentiation, in which RAGE
expression played a more important role in cellular
survival than in neurite outgrowth.
25 In this model,
inhibition of RAGE function partially blocked the
increase in levels of the anti-apoptotic protein Bcl-2
in the process of neuronal differentiation,
25 indicating
that RAGE and its signaling also might contribute to
the survival of certain cancer cell types undergoing
‘‘differentiation’’. Furthermore, although indirectly,
our previous study demonstrated that NF-jB, cur-
rently considered as a causative transcriptional factor
for various inﬂammatory events and also known as a
major RAGE-mediated signal, played an important
role in the survival of neuronal tumor cells
26,27 and in
experimentally developed HCC.
28
The present study demonstrated that increased
RAGE expression was highly associated with the
status of pathological ‘‘diﬀerentiation’’ in HCC,
which played a signiﬁcant role in acquisition of the
hypoxia-resistant phenotype of tumor cells. This
conclusion is supported by several lines of experi-
mental evidence. First, the level of RAGE expres-
sion was higher in well- and moderately
diﬀerentiated HCC, while it diminished as the tu-
mors dediﬀerentiated to poorly diﬀerentiated HCC.
This was consistent with the evidence that a negative
correlation was observed between the level of
RAGE mRNA expression and either the level of
PIVKA II or the incidence of postoperative recur-
rence. Second, the analysis of ﬁve HCC lines re-
vealed that three of these (Li7, Hep3B, and HuH7)
that are resistant to hypoxic stress characteristically
showed higher levels of RAGE expression compared
to the two hypoxia-intolerant cell lines HepG2 and
HT17. Third, sublethal hypoxia exposure induced
signiﬁcantly increased RAGE expression in hypoxia-
resistant HCC lines. In the analysis of the associa-
tion between the level of RAGE expression and the
‘‘diﬀerentiation status’’ of HCC lines, the level of
RAGE expression was higher in ‘‘possibly diﬀeren-
tiated’’ lines (i.e., HCC with low Alpha-Fet protein
(AFP) production), consistent with the results
from clinical samples. Finally, cells overexpressing
RAGE exogenously showed prolonged survival un-
der hypoxic conditions compared to control mock-
TABLE 2. Relationship between tumor RAGE expression
and clinicopathological features
Factors
Tumor RAGE mRNA
expression
p value n Mean ± SD
Gender
Male 30 2.267 ± 0.341 0.03
female 6 2.777 ± 0.619
Age
‡65 years 26 2.468 ± 0.568 0.03
<65 years 10 2.052 ± 0.638
Tumor size (mm)
‡30 11 2.395 ± 0.613 0.39
<30 25 2.333 ± 0.620
Portal invasion
Absent 22 2.358 ± 0.655 0.52
Present 14 2.348 ± 0.594
Venous invasion
Absent 26 2.339 ± 0.577 0.47
Present 10 2.357 ± 0.633
Vascular invasion
Absent 19 2.362 ± 0.633 0.46
Present 17 2.340 ± 0.601
Intrahepatic metastasis
Absent 27 2.378 ± 0.662 0.33
Present 9 2.273 ± 0.435
Gross classiﬁcation
Localized type 21 2.448 ± 0.636 0.13
Invasive type 15 2.217 ± 0.564
Differentiation
Well 4 2.365 ± 0.566
0.43
Moderately 28 2.420 ± 0.580
0.08
Poorly 4 1.860 ± 0.783
Stage
I,II 16 2.367 ± 0.643 0.55
III,IV 20 2.340 ± 0.597
PIVKAU
Normal 9 2.704 ± 0.385
High 25 2.186 ± 0.630 0.03
AFP
Normal 12 2.557 ± 0.586 0.16
High 24 2.250 ± 0.607
Virus
B 7 2.237 ± 0.606
C 21 2.382 ± 0.569
None 8 2.374 ± 0.779
Recurrence
Absent 25 2.485 ± 0.628 0.04
Present 11 2.050 ± 0.456
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strated similar results.
Our conclusion also provides a new hypotheti-
cal concept that hepatic RAGE expression may be
relevant to the stage or severity of inﬂammation and
the incidence of carcinogenesis and early tumorigen-
esis of HCC (Fig. 7). In the process of the develop-
ment of an HCC lesion, increased RAGE expression
b a
c d
well
mod.
poorly
3
10
8
(70)* 7
(68)** 18
(20) 2
positive negative
*:p<0.05 vs poorly, **:p<0.03 vs poorly
( ) positve rate
RAGE expression
FIG. 3. RAGE expression by immunohistochemical staining: (a) well-differentiated HCC, (b) moderately (mod.) differentiated HCC, (c)
poorly differentiated HCC, (e) the number of RAGE positive or negative cases according to tumor differentiation.
RAGE transfected
Cos7
Mock Cos7 Li7 2 G p He Hep3B HuH7
(Well)
HT17
(Poorly)
B-actin
2 1 e n a L 3 5 4 6 7
7 i L B 3 p e H 7 H u H
A N A N A N
B-actin
FIG. 4. (a) RAGE expression in hepatoma cell lines by
Western blotting. (b) RAGE expression in hepatoma cell lines
under hypoxic conditions by Western blotting. N, normoxic
conditions; A, anaerobic conditions.
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advanced hypoxic environment during remodeling
and carcinogenesis with accelerated cell proliferation.
In this context, an HCC lesion which is highly asso-
ciated with inﬂammation caused by either hepatitis
viruses or drugs is developed through a process of
multistage carcinogenesis, i.e., from inﬂammatory
lesions (e.g., hepatitis, cirrhosis and precancerous le-
sion) to adenomatous hyperplasia, and eventually
into HCC. Once cancer is established, HCC dedif-
ferentiates step-by-step to a more malignant histol-
ogy, from well- and moderately to poorly
differentiated HCC. It has also been pointed out that
the vascular supply changes signiﬁcantly between
each stage of tumorigenesis. According to the evi-
dence from several clinical studies,
15,29,30 both ade-
nomatous hyperplasia and well-differentiated HCC
are hypovascular tumors primarily fed by the portal
vein system, while moderately and poorly differenti-
ated HCC are hypervascular tumors primarily fed by
arterial blood. In addition, early carcinogenesis and
the development of the malignant phenotype gener-
ally occur in an avascular environment.
31–33 In-
creased RAGE expression, at least in part, may thus
play an important role in the mechanism of early
HCC development from precancerous inﬂammatory
lesions. In addition, about the expression of RAGE
being lower in poorly differentiated HCC when
compared to well and moderately differentiated
HCC, gastric and colon cancers have been showed
that RAGE and other ligands interacts act on tumor
promotion in clinical materials.
9,11 However, prostate
cancer was demonstrated to show no correlation be-
tween RAGE expression and tumor differentiation
and depth.
14 Moreover, non-small-cell lung cancers
have been showed a reverse correlation between
RAGE expression and tumor stage.
34 This result is
partially similar to our results. RAGE expression of
each clinical samples is various.
Some reports have shown that RAGE-expressed
cells have invasion and migration potential. Our
data from clinical samples did no relate to the po-
tential. In vivo, invasive and metastatic potential are
reﬂected by many factors, which may have caused
our results.
Our results raise many questions concerning
mechanistic and practical processes. It is important to
know whether RAGE can bind HMGB1 secreted
from activated macrophages in hepatic inﬂammation,
or if occupancy of RAGE by inhibitors would obvi-
ate binding of the stimulatory ligands. The functional
role of downstream signaling of the RAGE would
also be important to determine the cytoprotective
mechanism under hypoxia.
Our ﬁndings have provided the ﬁrst evidence of the
clinical relevance and function of RAGE in HCC,
namely diﬀerentiation-associated RAGE expression
that confers a hypoxia-resistant phenotype. Although
other mechanisms may also be important, our
data also introduce the concept that RAGE and its
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FIG. 5. Comparison of cell survival of RAGE-transfected Cos7 and mock-transfected Cos7 cells under anaerobic conditions. Cell survival of
both groups was estimated from six dishes at each time point using the MTT assay. *p < 0.01 by Students t-test.
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targets in the treatment of HCC.
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